Future Fields' EntoEngine™ platform produces serum-free, bioactive growth factors and other recombinant proteins more sustainably than traditional expression systems.
Future Fields' EntoEngine™ deploys Drosophila melanogaster - or the common fruit fly. The company supercharge this tiny but mighty organism with synthetic biology and scale it with the efficiencies of insect farming. The end result? Active, sustainable, and cost-effective biomolecules.
Biomolecules produced by the EntoEngine™ are optimized for food, health, and life science research innovations.